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BACKGROUND: Brain iron deposition occurs in dementia. In European ancestry populations, the HFE 
p.C282Y variant can cause iron overload and hemochromatosis, mostly in homozygous males.  
OBJECTIVE: To estimated p.C282Y associations with brain MRI features plus incident dementia 
diagnoses during follow-up in a large community cohort.   
METHODS: UK Biobank participants with follow-up hospitalization records (mean 10.5 years). MRI in 
206 p.C282Y homozygotes versus 23,349 without variants, including T2* measures (lower values 
indicating more iron).  
RESULTS: European ancestry participants included 2,890 p.C282Y homozygotes. Male p.C282Y 
homozygotes had lower T2* measures in areas including the putamen, thalamus, and hippocampus, 
compared to no HFE mutations. Incident dementia was more common in p.C282Y homozygous men 
(Hazard Ratio HR=1·83; 95% CI 1·23 to 2·72, p=0.003), as was delirium. There were no associations 
in homozygote women or in heterozygotes.  
CONCLUSION: Studies are needed of whether early iron reduction prevents or slows related brain 
pathologies in male HFE p.C282Y homozygotes.   
 






Iron has been linked to dementia and other neurodegenerative diseases, with roles in oxygen transport, 
myelin production plus synthesis and metabolism of neurotransmitters [1–3]. Several rare genetic 
‘Neurodegeneration with Brain Iron Accumulation’ syndromes have been described [4]. Iron 
accumulation in specific brain areas is found in Alzheimer’s disease (the most common form of 
dementia), beyond normal accumulations seen in aging [5], and these iron accumulations are 
associated with amyloid plaques and tau aggregation [5].  Chelator treatment to remove iron has shown 
promise in Alzheimer’s disease animal models [5] and in human randomized trials, with some evidence 
of slowing of cognitive decline [6].  
 
The homeostatic iron regulator ‘HFE’ gene p.C282Y variant relaxes controls on iron absorption from 
the gut, leading to moderately raised serum iron levels [7] in heterozygotes. In homozygote males 
especially, the variants can result in iron overload and iron deposition in many tissues [8]. Male p.C282Y 
homozygotes are at substantially increased risks of developing clinical hemochromatosis, with related 
liver cirrhosis and liver carcinomas, arthritis, osteoporosis and diabetes [9].  Iron overload in p.C282Y 
homozygote women is less common [7], likely due to iron losses in menstruation. Iron overload can 
occur but is unusual in p.C282Y and p.C282Y/H63D heterozygotes [9]. In northern European Ancestry 
populations, the p.C282Y variant is carried by 10-15%, with approximately 1 in 150 (0·67%) being 
homozygous [10]. In North America, p.C282Y homozygosity prevalence is 0·44% in non-Hispanic 
whites, but much less common in other ancestry groups [7]. Iron overload in hemochromatosis is 
prevented and treated with phlebotomy [8], but many patients are currently diagnosed only after 
irreversible morbidity has developed.  
 
There have been several reports of associations between HFE genotypes and dementia, but a recent 
multi-study case-control meta-analysis of the p.C282Y mutation rs1800562 and Alzheimer’s disease 
reported no association [11]. However, this analysis tested overall genotype associations (which are 
dominated by the large numbers of heterozygotes) and did not analyze homozygote males separately 
[11]. It therefore remains unclear whether p.C282Y homozygote men or women have increased risks 




Given the paucity of evidence, we aimed to test associations between the hemochromatosis (type 1) 
associated genotypes (HFE p.C282Y homozygotes and heterozygotes, plus p.C282Y/H63D status) 
and; 1) brain features on MRI, and 2) incident dementia recorded during hospitalization. We used data 
from UK Biobank (UKB) European descent participants (n=335,909), including 28,860 MRI imaging 
volunteers. We hypothesized that p.C282Y homozygous males would be at most risk from brain iron 
deposition plus dementia during follow-up, as this group has substantially higher risks of other 
hemochromatosis morbidities [9]. UKB consent does not allow individual feedback of genotypes, so the 
medical care and records used in the analyses were not altered by UKB identified genotypes. 
 
MATERIALS AND METHODS 
Ethical approval  
UKB ethical approval was from the North West Multi-Centre Research Ethics Committee. The current 
analysis was approved under UKB application 14631 (PI David Melzer). 
 
Data and Participants  
UKB included 502,634 volunteers aged 40 to 70 years old at recruitment, living near 22 assessment 
centers in England, Scotland and Wales [12]. Baseline assessments (2006 to 2010) included disease 
history [12] and participants consented to genotyping, plus record linkage to the UK National Health 
Service hospitalization routine datasets.  
 
Genotypes  
As HFE p.C282Y mutations are relatively common only in European ancestry groups [7], we used data 
for European ancestries participants with HFE p.C282Y (rs1800562) genotype information, and also for 
HFE p.H63D (rs1799945). UK Biobank used Affymetrix microarrays (800,000 markers directly 
genotyped), but as rs1800562 (p.C282Y) was not genotyped, standard imputation methods were 
applied [13] (see Supplementary Methods for details). Imputed p.C282Y genotypes (rs1800562) were 
highly correlated with exome sequencing genotypes (from 49,772 participants, r2=0·998) and only one 
(of 231, 0·4%) imputed p.C282Y homozygotes was incorrectly classified (sequenced genotype = 





Magnetic Resonance Imaging (MRI) phenotypes were from the UKB brain image-processing pipeline 
[14]. A standard Siemens Skyra 3T running VD13A SP4, with Siemens 32-channel RF receive head 
coil was used. Measures included T2* signal loss, an indicator of magnetic susceptibility influenced 
mainly by iron in deoxyhemoglobin, storage proteins and myelin [15]. Given strong correlations between 
right and left hemisphere T2* iron deposition measures (correlation 0·48 to 0·79, all p<0·0001), mean 
values for right and left hemisphere matching variables were used in primary analyses, to reduce 
multiple statistical testing. However, left and right separate analyses were performed for sensitivity 
analysis. 
 
Data for MRI analyses were from participants who met the inclusion criteria (scanned May 2014 to 
2018), with results of analyses of included participants irrespective of completeness of all derived MRI 
measures, with additional analysis for those with full data on all derived brain MRI measures.  
 
Diagnoses and Follow-up 
Incident diagnoses were from UKB hospitalization routine datasets to March 2020 for England (Hospital 
Episode Statistics), October 2016 for Scotland (Scottish Morbidity Record) and February 2016 for Wales 
(Patient Episode Database for Wales). The maximum inpatient follow-up was 14·1 years, mean 10·5 
years. Incident diagnoses were ascertained from recorded International Classification of Disease 10th 
revision codes, including those for dementia (F00*; F01*; F02*; F03*; G30*);   Mild Cognitive Impairment 
(MCI; ICD-10 codes: F06·7); delirium (ICD-10 codes: F05*) and for stroke or Transient Ischemic Attack 
(TIA; ICD-10 codes: G45-G46*; I61*; I63*). Analyses of each incident condition excluded participants 
with respective prevalent diagnoses at baseline, based on participant responses at baseline interview 
plus ICD-10 coded hospitalization records from 1996 to baseline interview (see Supplementary 
Methods). For example, participants reporting doctor diagnosed dementia at baseline interview and 
those with dementia in hospitalization data before baseline interview were excluded from incident 
dementia analyses. Dementia diagnosis accuracy in English hospital records has been validated 
(sensitivity 78%, specificity 92%) [16] and Scottish routine data (positive predictive value 87%) [17]. In 
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our preparatory analyses, Apolipoprotein E (ApoE) e4/e4 type was strongly associated with the 
recorded incident dementia diagnoses (OR=7·8 95% CI: 7·0 to 8·6, versus e3/e3), as expected.  
 
Statistical analysis  
All UK Biobank participants of European genetic ancestry with the hemochromatosis (type 1) related 
genotype data were included in analyses: i.e. HFE p.C282Y homozygotes and (simple) heterozygotes, 
plus p.C282Y/H63D compound heterozygotes, plus those with neither variant as a comparison group. 
Participants with the H63D heterozygote and homozygote variant only were excluded, as these 
genotypes are not risk factors for hemochromatosis. Given that HFE p.C282Y homozygotes (mainly 
men) and to a lesser extent the p.C282Y/H63D genotype are at most risk for iron overload, analyses 
and reporting focusses on these genotypes. See Supplementary Methods for details and 
Supplementary Table 1 for participant numbers for the studied genotype groups.  
We excluded the relatively small number of participants without imputed genotypes (n=15 233/502 642, 
3·0%) and those with imprecise p.C282Y imputation (n=183/487 409, 0·04%). Also, pparticipants who 
were p.H63D homozygotes (n= 10,258) or p.H63D heterozygotes (n= 105,019) only were excluded 
from diagnosis analyses, and from the MRI sub-study (n=802 and n=8,976 respectively), as this 
genotype causes modestly higher blood iron levels but is not associated with iron overload. MRI 
measures were quantile normalized and z-transformed before analysis.  
For MRI analyses, we hypothesized that T2* iron deposition associated measures were most likely to 
be associated with HFE genotypes, followed by gray matter volumes. However, to be conservative and 
complete, we analyzed all available UK Biobank produced MRI measures, with Benjamini-Hochberg 
adjustment for multiple testing applied across all imaging phenotype associations (n=481 tests in 
p.C282Y homozygotes), to limit the false discovery rate at 5%. Linear regression was used to test 
associations between HFE genotypes (p.C282Y homozygotes, p.C282Y/H63D compound 
heterozygotes, and p.C282Y heterozygotes) and MRI measures (after calculating mean left and right 
measures as above), compared with having neither mutations, in males and females separately.   
Cox proportional hazards regression was used to test genotype associations with incident diagnoses. 
All models were stratified by sex, and adjusted for population genetics sub-structure using the first ten 
principal components generated in European-descent participants, genotyping microarray (Affymetrix 
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Axiom array for 90% and Affymetrix BiLEVE array for 10% of participants, sharing >95% content), 
assessment center, plus age at baseline assessment. The model estimating associations between 
genotype and incident dementia was also adjusted for ApoE genotype, and the interaction between the 
genotype and ApoE e4 specifically was tested for, since previous studies have suggested an interaction 
between the HFE gene and ApoE e4 in conferring risk for Alzheimer’s disease[18][19]. There were no 
violations of proportional hazards assumptions for our principal outcome (dementia) in Cox models. 
Analyses used Stata v15·1, and `stcox` function for Cox models. In sensitivity analyses, we also 
excluded one randomly selected participant from each pair of participants related to the third degree 
(n= 53,376) leaving 282,533 unrelated participants, to avoid possible inflation of associations from 
family relatedness. In an additional sensitivity analysis focused on older subjects who are more likely 
to develop dementia, we excluded participants aged under 60 years (n = 186,422) leaving 149,487 
participants. A further sensitivity analysis excluded participants with hemochromatosis diagnosed at 
baseline (n=321), to provide separate estimates for community identified undiagnosed participants (n = 
335,588).  
Missing data: UK Biobank derived MRI gray matter volume measures were available for slightly more 
participants than for T2* measures: we therefore provide analyses of all participant data for each brain 
MRI measure, and additional analyses including only participants with a full set of MRI measures. 
Diagnosis data during follow-up were from all available hospital inpatient records. 
 
RESULTS 
MRI measure associations  
Data from the UK Biobank brain MRI sub-study were available (Table 1) including 78 male and 128 
female p.C282Y homozygotes, plus 11,082 male and 12,257 female participants with neither HFE 
variant. Overall participation in brain MRI was slightly more common in males (OR=1·06 95%CI 1·04 to 
1·09) and slightly less common with advancing age (OR=0·970 CI 0·969 to 0·971 per year increase in 
age). However, male p.C282Y homozygotes in UK Biobank were less likely to participate in the MRI 
sub-study (5·95% of 1,294 homozygote males versus 8·94% of men with neither p.C282Y nor p.H63D 
mutations: OR=0·68 95%CI 0·54 to 0·85). Eleven male p.C282Y homozygote MRI participants (of the 
78, 14·1%) were diagnosed with hemochromatosis at UK Biobank baseline, compared to 12·1% in the 
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1,294 homozygote males included in diagnosis analyses. Female p.C282Y homozygote participation in 
the MRI subset was similar to participation with neither HFE mutation.  
 
Data on T2* signal loss (lower measures associated with more iron deposition) were available for 78 
male and 128 female homozygotes (Table 2). T2* measures were substantially lower in male p.C282Y 
homozygotes compared to those with neither variants across a number of brain regions including the 
putamen, caudate, nucleus accumbens, but notably also within important cognitive regions: the 
thalamus (beta = -0·90 standard deviations ‘sd’, 95% CI -1·12 to -0·68, Benjamini-Hochberg multiple 
testing adjusted p-value=1·4*10-13) and hippocampus (beta= -0·32 sd, 95%CI -0·52 to -0·13, adjusted 
p=0·022). For illustration (Figure 1), we present T2 fluid attenuated inversion recovery (FLAIR) images 
from a male homozygote with the nearest to group T2* putamen measure, versus a similar image from 
an age and sex-matched participant without HFE mutations.  
 
Smaller gray matter volumes were found in the putamen of male C282Y homozygotes (beta -0·86 sd, 
95%CI -1·08 to -0·64, adjusted p=1·8*10-12), caudate, several cerebellar regions, and the ventral 
striatum, compared to neither variants (see Supplementary Tables 2 and 3 for full results). Results of 
left and right hemisphere measures analyzed separately were similar (Supplementary Tables 4 and 5). 
In a sensitivity analysis including participants with complete MRI measures only (Supplementary Tables 
6 and 7) results were also similar to those presented above.  
 
In women, there were also associations between p.C282Y homozygote status and T2* measures within 
the putamen, thalamus, caudate, and pallidum (Table 2).  Lower gray matter volumes were observed 
in the putamen, caudate, thalamus, ventral striatum, and regions of the cerebellum (adjusted p<0·05). 
In male and female C282Y/H63D heterozygotes and in the other HFE genotype groups there were 
similar associations, but effect sizes were substantially smaller (≤0·5 standard deviations - see 




Disease associations  
Analyses of incident diagnoses during follow-up included UKB participants of European descent, aged 
40 to 70 years at baseline (mean 56·8 years, SD 8·0) (Table 1). Only 12·1% (156/1294) of male and 
3·4% (54/1596) of female p.C282Y homozygotes had been diagnosed with hemochromatosis (Table 1) 
at UK Biobank baseline interview. (See Supplementary Table 1 for details of studied HFE genotypes 
including p.C282Y heterozygotes). 
During follow-up, 25 male homozygotes (16 female) and 1,358 males without HFE variants were 
diagnosed with incident dementia (Table 1; Supplementary Table 1). Male p.C282Y homozygotes had 
increased hazards for incident dementia (HR 1·83, 95% CI 1·23 to 2·72, p=0·003, compared to those 
with neither p.C282Y nor p.H63D) (Figure 2). This association was similar after additionally adjusting 
for ApoE genotype status (HR 1·83, 95% CI 1·23 to 2·73, p = 0·003) and there was no statistically 
significant interaction between any p.C282Y/H63D genotype and ApoE e4 (p > 0.05). To remove 
potential bias from multiple family members, in a sensitivity analysis we included only one participant 
from those related to the third degree or closer (n= 130,275 after exclusions): the male homozygous 
association with dementia was similar (HR=1·88, 95% CI: 1·22 to 2·90, p = 0·004). To focus on 
dementia onsets in later life only, we included only participants aged 60 years or above at baseline in a 
sensitivity analysis (n= 70,710 after exclusions): the male homozygous association with incident 
dementia was relatively unchanged (HR=1·73, 95% CI: 1.13 to 2.67, p = 0·01; Supplementary Table 
9). The association between male p.C282Y homozygosity and incident dementia remained significant 
after excluding 242 participants with hemochromatosis diagnosed at baseline from the total sample 
(n=153,446) (HR: 1.81, 95% CI: 1.19 to 2.76, p = 0.01; Supplementary Table 10). 
To extend the evidence of association between p.C282Y homozygosity and dementia in men, we 
additionally tested associations with Mild Cognitive Impairment, Delirium, and Stroke or Transient 
Ischemic Attack diagnoses. There were increased hazards for diagnosis of incident delirium in p.C282Y 
homozygote males (HR 1·82, CI 1·21 to 2·72, p=0·004), but no association with Mild Cognitive 
Impairment, or Stroke and Transient Ischemic Attack.  
In female C282Y homozygotes and the heterozygote HFE variants in either sex, there were no 





We aimed to estimate hemochromatosis genotype associations with brain MRI measures and incident 
dementia in the UKB community genotyped cohort, with a specific focus on male HFE p.C282Y 
homozygotes, who develop the majority of hemochromatosis related physical diseases. We found 
associations in p.C282Y homozygote men with lower T2* measures (associated with greater iron 
deposition [15]) in several areas involved in dementia, including the hippocampus and thalamus. In 
addition, we found lower gray matter volumes including in the putamen and ventral striatum. In the main 
UK Biobank sample (n=335,909) we found a substantial increase in hazards for incident dementia 
diagnoses during hospitalization in p.C282Y homozygote men HR=1·83 95%CI 1·23 to 2·72) during 
the mean 10·5 year follow-up, plus increased hazards for delirium, for which dementia is a major risk 
factor [20].  Overall, these results suggest that p.C282Y homozygosity is a significant risk factor for 
dementia in men with European ancestries. Associations between p.C282Y heterozygous status and 
dementia were not statistically significant.  
It is difficult to compare our findings with similar community studies with sufficient numbers of p.C282Y 
homozygote men or women, because UKB contains nearly 10 times more such participants than the 
previously largest similar study [9], yielding far more statistical power to detect associations. As noted, 
iron deposition has been linked to core Alzheimer’s disease pathologies, with iron being bound by 
Alzheimer’s associated amyloid β and tau, and also involved in formation of oligomeric tau [2]. A recent 
meta-analysis of the p.C282Y variant (HFE rs1800562, plus the transferrin variant rs1049296) found 
no association with Alzheimer’s disease, but no results were provided on the homozygote mutation in 
either men or women. In UK Biobank, a similar analysis of rs1800562 also produces no overall 
association with incident dementia, but this is because there were 64,458 heterozygotes 
(Supplementary Table 1) and only 2890 homozygotes in analyses. An earlier meta-analysis[21] of 
p.C282Y dementia association studies included data on only 18 p.C282Y homozygote cases and 37 
controls and reported no association, while another meta-analysis [22] studied 16 p.C282Y 
heterozygotes and reported reduced Alzheimer’s disease risks, but included no data on homozygotes.    
The brain areas with associated iron deposition in p.C282Y homozygote men included the hippocampus 
and thalamus, two structures known to play important roles in memory function [23], and which are 
frequently affected in early Alzheimer’s disease [24], as well as in the putamen, where iron accumulation 
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occurs with aging [25] and in geriatric depression [26]. Smaller putamen gray matter volumes have 
been reported in neurodegenerative disorders [27], including Alzheimer’s disease [28].   
De Barros et al[29] recently reviewed the evidence on correlations between MRI relaxation measures 
and direct physical measures (including mass spectrometry) of iron in brain samples, and reported 
overall high linear correlations. These correlations were strong in the basal ganglia (Pearson correlation 
coefficient r = 0.90) and grey matter, but there was little correlation in white matter, which  Langkammer 
et al[30] postulated might be due to the effects of paramagnetic iron and diamagnetic myelin. The higher 
iron versus MRI relaxation correlations in the basal ganglia and grey matter is consistent with our 
reported C282Y associations being concentrated in these areas.  
Limitations  
The main limitation of this analysis is that dementia sub-type data are limited in UKB hospitalization 
records: within the male p.C282Y homozygotes with dementia, specific diagnoses were Alzheimer's 
disease (seven participants, ICD-10 F00 & ICD-10 G30); vascular dementia (four participants, ICD-10 
F01); dementia in other specified diseases classified elsewhere (three participants, ICD-10 F02) and 
unspecified dementia (n=11, ICD-10 F03). More work is therefore needed to systematically assess 
specific dementia pathologies, including in those not hospitalized. Unfortunately there is currently little 
known about the molecular localisation of excess iron in the brains of patients with hemochromatosis 
e.g. whether the iron is present as hemosiderin deposition, in some ferritin bound form, or in some other 
form. Also, UKB volunteers tended to have somewhat less morbidity and lower prevalence of health 
risk factors at baseline compared to the UK population [31], but this should have limited impact on our 
estimates, which are based on incident diagnoses during follow-up only in those free of dementia 
diagnoses at baseline. In female p.C282Y homozygotes and in heterozygotes, brain iron deposition 
appeared less marked, but longer follow-up will be needed to exclude associations with dementia. 
These findings add to the extensive excess physical morbidity reported in p.C282Y homozygote males, 
including excess liver disease, arthritis, diabetes, osteoporosis, and pneumonia [9]. More work is 
needed to confirm that the excess dementia and delirium seen in male p.C282Y homozygotes is 
causally related to the iron deposition directly rather than by a secondary mechanism, for example as 
a consequence of co-existing liver cirrhosis. However, in our study sample, only one p.C282Y 
homozygote male with dementia had also been diagnosed with liver cirrhosis or fibrosis. Iron excess is 
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usually easily and safely treated with venesection [8], and therefore early diagnosis and treatment of 
HFE p.C282Y homozygote men may results in lower rates of dementia and delirium, whether these 
conditions are due to excess iron directly or from a secondary causal mechanism.  Clinical trials may 
also be needed to establish whether dementia in this group responds to iron reduction therapy.  
In summary, men with the HFE p.C282Y homozygous mutation developed substantially more marked 
brain iron deposition in dementia relevant brain areas. In addition, p.C282Y homozygote men were 
more likely to be diagnosed with dementia during a 10·5 year mean follow-up in hospitalization data. 
Studies are needed of whether early ascertainment of hemochromatosis and intervention in HFE 
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Table 1: Characteristics of participants included in the imaging and disease analyses, by 








HFE variant  
 
C282Y+ 





/H63D+ C282Y +/+ 
MRI subgroup         
 Total number 11,082 468 78  12,257 453 128 
 Age – mean (sd)  64·2 (7·7) 64·3 (7·9) 63·1 (8·3)  63·0 (7·4) 63·2 (7·3) 64·7 (7·5) 
 
 
Diagnosis study  
 Number of participants 122,860  4,955  1,294   145,719  5,746  1,596  
 Age (baseline) – mean (sd)    57·0 (8·1) 56·9 (8·1) 56·8 (8·2)  56·6 (7·9) 56·5 (7·9) 56·9 (8·0) 
 Hemochromatosis                             
diagnosis (baseline) 30 29 156  8 12 54 
 Incident diagnoses*        
 Dementia  1,358 64 25  1,164 47 16 
 MCI 210 9 3  147 9 3 
 Delirium 1,313 61 24  932 38 14 
 Stroke/TIA 2,895 131 39  2,148 81 17 





Table 2: Brain MRI median T2* and gray matter volume associations from linear regressions, 
comparing HFE p.C282Y homozygotes to those without p.C282Y or p.H63D variants), in males and 













Males      
Median T2* measures (72 HFE p.C282Y homozygotes vs. 9,304 controls) 
 Putamen -0·91 -1·13 -0·70 1·0*10-16 4·9*10-14 
 Thalamus -0·90 -1·12 -0·68 5·7*10-16 1·4*10-13 
 Caudate -0·55 -0·79 -0·32 3·4*10-6 2·1*10-4 
 Nucleus Accumbens -0·40 -0·61 -0·19 2·2*10-4 6·6*10-3 
 Pallidum -0·33 -0·52 -0·13 8·6*10-4 2·2*10-2 
 Hippocampus -0·32 -0·52 -0·13 9·2*10-4 2·2*10-2 
      
Gray matter volume (77 HFE p.C282Y homozygotes vs. 10,364 controls)  
 Putamen -0·86 -1·08 -0·64 1·1*10-14 1·8*10-12 
 Ventral Striatum -0·71 -0·92 -0·50 8·0*10-11 9·8*10-9 
 Vermis IX Cerebellum -0·80 -1·04 -0·55 1·7*10-10 1.6*10-8 
 V Cerebellum -0·66 -0·89 -0·42 4·3*10-8 3·5*10-6 
 I-IV Cerebellum -0·57 -0·81 -0·33 2·7*10-6 1·9*10-4 
 Vermis VIIIb Cerebellum -0·49 -0·71 -0·27 1·3*10-5 6·4*10-4 
 Vermis VIIb Cerebellum -0·50 -0·75 -0·25 9·7*10-5 3·6*10-3 
 Vermis X Cerebellum -0·54 -0·81 -0·27 9·0*10-5 3·6*10-3 
 Vermis VIIIa Cerebellum -0·46 -0·70 -0·22 1·9*10-4 6·4*10-3 
 Caudate -0·37 -0·60 -0·14 1·8*10-3 3·8*10-2 
 Vermis VI Cerebellum -0·38 -0·62 -0·13 2·3*10-3 4·2*10-2 
            
Females      
Median T2* measures (113 HFE p.C282Y homozygotes vs. 10,491 controls)  
 Putamen -0·88 -1·07 -0·69 5·3*10-19 2·6*10-16 
 Thalamus -0·70 -0·87 -0·53 1·6*10-15 2·3*10-13 
 Caudate -0·57 -0·77 -0·37 2·0*10-8 1·2*10-6 
 Pallidum -0·41 -0·59 -0·24 4·4*10-6 1·8*10-4 
      
Gray matter volume (128 HFE p.C282Y homozygotes vs. 11,537 controls)  
 Putamen -0·78 -0·96 -0·59 5·5*10-16 1·3*10-13 
 Vermis IX Cerebellum -0·74 -0·92 -0·56 1·9*10-15 2·3*10-13 
 Ventral Striatum -0·62 -0·78 -0·45 6·6*10-14 6·4*10-12 
 Vermis VIIIa Cerebellum -0·53 -0·70 -0·36 6·7*10-10 4·7*10-8 
 V Cerebellum -0·47 -0·64 -0·29 1·0*10-7 5·6*10-6 
 Vermis VIIb Cerebellum -0·42 -0·59 -0·25 2·0*10-6 9·6*10-5 
 I-IV Cerebellum -0·37 -0·52 -0·21 4·2*10-6 1·8*10-4 
 Vermis VI Cerebellum -0·40 -0·58 -0·23 4·8*10-6 1·8*10-4 
 Vermis VIIIb Cerebellum -0·40 -0·57 -0·23 5·9*10-6 2·0*10-4 
 Caudate -0·42 -0·61 -0·22 2·2*10-5 6·7*10-4 
 Vermis X Cerebellum -0·30 -0·47 -0·13 4·5*10-4 1·1*10-2 
 Thalamus -0·29 -0·47 -0·11 1·7*10-3 3·2*10-2 
 Vermis Crus II Cerebellum -0·26 -0·43 -0·09 2·8*10-3 4·8*10-2 
Note: linear regression models for mean of left and right measures, adjusted for age, imaging assessment 
center, microarray, and genetic principal components 1-10. Beta = standard deviation difference in MRI imaging 
phenotype between C282Y homozygous group and neither p.C282Y nor p.H63D variants. CIs = confidence 
intervals. Adjusted P = Benjamini-Hochberg adjusted p-values for 481 tests. See Supplementary Tables 2 and 3 




Figure 1: MRI T2 FLAIR axial images for male participants closest to respective mean 
putamen T2* values with p.C282Y homozygote variants (right) and neither HFE variant (left, 
‘WT’). In the highlighted square, cortical(1) and white matter(2) intensity appears similar in 
both images, but the p.C282Y homozygote image shows relative hypo-intensity (associated 
with iron deposition) in the putamen (3) and globus pallidus (4). Images provided by UK 
Biobank© under license. 
 
Notes: WT = wild type or neither p.C282Y nor p.H63D mutations present. See details of image 





Figure 2: Association between hemochromatosis risk HFE genotypes and incident diagnoses: 
Hazard ratios (95% Confidence intervals) compared to those with neither HFE mutation.   
 
Notes: Cox proportional hazards regression adjusted for age, imaging assessment center, microarray, 
and genetic principal components 1-10. Excluding each respective diagnosis at baseline. Full results 
for heterozygotes are presented in Supplementary Table 8. 
